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The Authors Reply: Hallinan et al. underscore the ethical duty of research sponsors to share findings with trial participants and suggest that providing nontechnical and technical narrative summaries could help fulfill this obligation. Notably, the notice of proposed rulemaking for the FDA Amendments Act 1 has delayed enactment of these summaries, pending public feedback.
Additional issues are presented when sponsors delay reporting while pursuing marketing approval for novel products. We estimated that 44 to 45% of industry-funded trials (as compared with 6% of trials funded by the National Institutes of Health and 9% of other trials) were not required to report because they involved an unapproved or unlabeled product. Under proposed rules, sponsors seeking approval for new products or indications may delay reporting to ClinicalTrials .gov for 2 more years if a certification of delay is filed before the 1-year deadline. Trials involving unapproved products that do not include plans for seeking approval must report within 1 year. Although this rule ensures eventual public access to data, it also highlights tensions between desires to protect trade secrets and obligations to share knowledge. Furthermore, delays in public reporting may lead to unnecessarily duplicative trials and expose participants to unwarranted risks. Each bar represents an academic medical center or other nonprofit organization with 10 or more registered trials in the sample, arranged according to the total percentage of registered trials sponsored by that organization and estimated to be subject to at least one of the two proposed results-reporting requirements. Algorithms involving ClinicalTrials.gov data elements (http://prsinfo.clinicaltrials.gov/definitions.html) were used to estimate trials subject to each proposal. For the Food and Drug Administration Amendments Act of 2007 (FDAAA) Notice of Proposed Rulemaking (NPRM), the algorithm and data elements were an "Interventional" Study Type; a Study Phase other than "0" or "1," at least one Intervention Type as "Drug," "Biologic" (or "Genetic"), or "Device" (or "Radiation"); at least one Facility Country as "United States" or Investigational New Drug Application (IND) or Investigational Device Exemption (IDE) Status as "Yes" (not available publicly); and a Primary Completion Date (if missing, Study Completion Date) as "January 2008" or later. For the draft National Institutes of Health (NIH) policy, the algorithm and data elements were an "Interventional" Study Type and at least one NIH Institute or Center as Collaborator.
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